.RESEARCH STUDY EMPHASIZE.16 October 2024. In the NIAGARA trial, the add-on of perioperative durvalumab to standard therapy for muscle-invasive sac cancer cells enhanced event-free and also overall survival, denoting a new treatment possibility for this health condition.